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ORIGINAL ARTICLE
Tandem mass spectrometry (MS/MS) is a power-
ful technology that allows rapid and sensitive
measurement of amino acids and acylcarnitines
in small amounts of blood.1 Recently, high-
throughput MS/MS has been made possible
by improvements in hardware and automated
interpretation system and has, therefore, become
a very promising choice for neonatal screening.
A broad range of inborn errors, such as organic
acidemias, urea cycle disorders, and fatty acid
oxidation defects can be detected by MS/MS neona-
tal screening, making early therapeutic interven-
tions and reduction of mortality and morbidity
possible. On the other hand, MS/MS also detects
mild inborn errors2,3 in which protocols of 
patient management and counseling remain to
be established.
MS/MS neonatal screening has been success-
fully implemented in countries such as Australia,4,5
the United States,6 and in Europe.7 However, in
gAsian countries, the efficacy of MS/MS screenin
has not been established. In Taiwan, MS/MS
neonatal screening started in 20008 tand a pilo
study was published in 2001.9
In this study, we present our results for the
first time. We determined the prevalence of dis-
eases identified by MS/MS and evaluated the out-
come of the cases. We demonstrated that MS/MS
yscreening results in favorable outcome in man
critical disorders. In addition, our data indicated
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that 3-methylcrotonyl CoA carboxylase (3-MCC)
deficiency is common, but fatty acid oxidation
defect is rare in Taiwan.
Patients and Methods
During the period August 1, 2001 to July 30, 2004,
parents of 210,767 newborns were informed of the
availability of MS/MS screening and 199,922 new-
borns were screened (participation rate of 94.9%)
at the National Taiwan University Hospital neona-
tal screening center. This center randomly screened
around two-fifths of all newborns in Taiwan. Blood
spots were obtained from infants after 48 hours of
life and 24 hours of feeding. One 1/8-inch punch
of the blood spot was used and butylated amino
acids and acylcarnitines were analyzed10,11 using
either API 2000 or API 3000 (Applied Biosystems,
Foster City, CA, USA) and the spectra were analyzed
by Chemo View software (Applied Biosystems).
The compounds monitored (Table 1) were acyl-
carnitines and the amino acids alanine, arginine,
citrulline, glycine, leucine/isoleucine, methionine,
ornithine, phenylalanine, tyrosine, and valine.
High cut-offs for all compounds (Table 1) were
established as the mean plus four standard devi-
ations (+4 SD), while the low cut-offs for free
carnitine, C2-acylcarnitine, and C16-acylcarnitine
were set at −3 SD. For internal quality control, the
coefficient of variation was kept at less than
15%. The external quality control included refer-
ence materials from the Centers for Disease
Control (Atlanta, USA). The data were analyzed by
experienced metabolic disease specialists in our
center for interpretation and decision making.
When the results suggested an inborn error, 
another blood sampling on the Gutherie card
was requested. When the second test was posi-
tive, or the first test was highly suggestive, the
infant underwent a confirmation test at a referral
center.
Statistical analysis
Statistical analysis was performed using the
Mann-Whitney test. All values are expressed as
mean ± standard deviation (range). A p value 
yless than 0.05 was considered to be statisticall
significant.
Results
During a period of 3 years, 29 cases were detected
by MS/MS screening (Table 2). The overall preva-
lence was one per 6894 live births. If we excluded
hyperphenylalaninemia and hypermethionine-
mia, which can also be detected by traditional
methods, the prevalence became one per 10,522.
At the same time, 48 infants referred for confir-
mation tests were later proved to be normal.
Therefore, the positive predictive value was 37.7%.
The inborn errors identified included amino aci-
dopathy, organic acidemias, urea cycle disorders,
gand fatty acid oxidation defects (Table 2). Amon
them, 3-MCC deficiency represented more than
one-third of the cases. However, all of them were
asymptomatic, as was one case of medium-chain
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Table 1. Items monitored using tandem mass
spectrometry and the cut-off values*
Item Cut-off Item Cut-off
(μM) (μM)
Alanine 299.27 C5DC 0.15
Arginine 13.75 C5OH 0.46
Citrulline 17.55 C6 0.27
Glycine 249.40 C8 0.27
Leucine/ 171.66 C8:1 0.42
Isoleucine C10 0.32
Methionine 35.50 C10:1 0.27
Ornithine 49.24 C12 0.47
Phenylalanine 74.69 C12:1 0.25
Tyrosine 139.98 C14 0.58
Valine 139.23 C14:1 0.32
C1† 48.29 C14OH 0.14
C2† 38.72 C16† 4.93
C3 4.18 C16:1 5.00
C3DC 0.22 C16OH 0.14
C4 0.59 C18 2.00
C4DC 0.45 C18:1 2.58
C5 0.53 C18:1OH 0.12
*Values shown are the high cut-off values; †low cut-off values are
1.39mM for C1, 4.43mM for C2 and 0.36mM for C16.
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acyl-CoA dehydrogenase (MCAD) deficiency.
Owing to early detection by MS/MS, the babies
were closely monitored and therapeutic interven-
tion was started promptly. The course and treat-
ment of selected cases treated in our hospital,
including two cases of type I glutaric aciduria
(GA I), one case of maple syrup urine disease
(MSUD), and one case of type II citrullinemia
are described below.
GA I
Patient 1 was a full-term female infant with an ele-
vated glutarylcarnitine (C5DC) level (0.62 μM;
cut-off, 0.13 μM) in the first blood spot at the
age of 5 days. The repeated C5DC level at the age
of 14 days was 0.708 μM. She was brought to our
clinic at the age of 18 days. At that time, she already
had mild hypotonia. Urine gas chromatography
mass spectrometry (GC/MS) analysis showed a
large amount of glutaric acid. Brain magnetic reso-
nance imaging (MRI) at the age of 40 days re-
vealed prominent bilateral sylvian fissures and
subarachnoid spaces that suggested atrophy of
bilateral frontotemporal regions. Dietary therapy
(Xlys low Try analog, Nutricia) and oral carnitine
were prescribed from the age of 42 days. She was
followed-up to the age of 2 years 7 months and
showed normal development without encephalo-
pathic crisis, although she remained mildly 
hypotonic.
Patient 2 was also a full-term female infant.
Her initial C5DC level was 0.214 μ fM at the age o
4 days, but rose to 0.67 μM at the age of 25 days.
Physical examination at the age of 1 month
showed generalized hypotonia and hyperreflexia.
cUrine GC/MS showed a large amount of glutari
yacid. At the same time, electroencephalograph
showed mild cerebral dysfunction, and brain MRI
revealed frontotemporal atrophy. She was put on
kdietary therapy with a special formula and too
carnitine from the age of 37 days. At the age of 1
year 10 months, she had nearly normal develop-
ment except for mild hypotonia.
MSUD
This full-term male infant was well until the 9th
day of life, when his parents found that he was
slightly lethargic and the feeding decreased. At the
age of 10 days, the parents were notified of his
screening results (leucine/isoleucine, 1850 μM).
He was brought to hospital the next day. Because
of rapid progression of respiratory distress and
consciousness disturbance, peritoneal dialysis was
immediately started to stabilize his condition.
Brain MRI at the age of 19 days showed diffuse
brain edema. Dietary therapy including branch-
chain amino acid-free formula was prescribed.
He recovered well with tiny residual high signal
on follow-up brain MRI at the age of 8 months,
when he was only slightly delayed in develop-
ment (mental development index 80, psycho-
fmotor development index 82, by Bayley Scales o
Infant Development II).
Citrullinemia type II
This full-term male infant was found to have in-
creased blood citrulline level (22.1 μM; cut-off,
17.55 μ f M) by neonatal screening at the age o
5 days. Repeated citrulline level taken at the age
of 14 days was higher (71.3 μM), with simultane-
ous increased levels of phenylalanine, threonine,
 methionine, tyrosine, and arginine. At the age
of 1.5 months, he had mild jaundice (total bili-
rubin, 12.2 mg/dL; direct bilirubin, 3.62 mg/dL),
and elevation of aspartate aminotransferase (AST,
103 U/L) and α-fetoprotein (170,174 ng/mL;
Table 2. Results of neonatal screening using
tandem mass spectrometry (n = 29)
Disease n
Hyperphenylalaninemia 8
Hypermethioninemia 2
3-MCC deficiency 10
MSUD 2
GA I 2
Citrullinemia I 2
Citrullinemia II 1
Tyrosinemia 1
MCAD deficiency 1
3-MCC = 3-methylcrotonyl CoA carboxylase; MSUD = maple syrup
urine disease; GA I = glutaric aciduria I; MCAD = medium-chain
acyl-CoA dehydrogenase.
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normal neonatal, < 10,000 ng/mL). Liver biopsy
showed diffuse micro- and macrovesicular fatty
changes in the hepatocytes, with mild inflamma-
tion in the portal areas and canalicular cholestasis.
Jaundice subsided 1 month later. The citrulline
levels were around 200–400 μM and began to
decline after 5 months of age, when his liver en-
zymes returned to normal as well. Overweight,
puffy face, and persistent hepatomegaly were found
but improved gradually after 9 months of age.
Mutational analysis of the citrin gene revealed
homozygous 851del4 mutation. He had normal
development at the latest follow-up, when he
was 1 year 9 months old.
Other disorders
There were two cases suspected of having mild type
I citrullinemia, whose initial blood spot citrulline
levels were 43.7 μM and 24.1 μM, respectively.
Repeated plasma citrulline levels that confirmed
the diagnosis were 282 μM and 83.2 μM, respec-
tively. Both cases are asymptomatic, have normal
development, and require no treatment. There
was only one case of MCAD deficiency in our se-
ries and his initial C8-acylcarnitine was 2.57 μM
(cut-off, 0.27 μM). He is also asymptomatic.
Evaluating the efficacy of MS/MS—using
hyperphenylalaninemia as an example
To evaluate the efficacy of MS/MS neonatal
screening, we compared the first plasma phenyl-
alanine levels and the time at which treatment
was started between patients identified by bacte-
rial inhibition assay (BIA) or MS/MS. We found
that the mean initial phenylalanine level in the
MS/MS group tended to be lower, and the
MS/MS group received treatment much earlier
than the BIA group (p < 0.001; Table 3).
Cost
The average cost of MS/MS neonatal screening in
tTaiwan was US$8–12 per case. Reimbursemen
rby the Taiwan Foundation for Rare Disorders fo
the poor and Taiwan natives has allowed those
people to benefit from this program.
Discussion
MS/MS screening in Taiwan is detecting increas-
ing numbers of cases with 3-MCC deficiency,
which has never been met clinically in our expe-
yrience. The high proportion of 3-MCC deficienc
(34.5%, 10 in 29) in this series is remarkable
when compared to other reports (5.3%,5 4.5%,6
5.7%7 f). The reasons for this higher incidence o
3-MCC deficiency in Taiwan are unknown, and
rgenotyping of these patients may offer furthe
answers. In contrast to the higher proportion
(30%,5 46%,6 15%7 r) of MCAD deficiency in othe
series,5–7 we detected only one case (3.4%, 1 in 29).
The low incidence of MCAD in Taiwan suggests
ythat fatty acid oxidation defects may be relativel
rare in Asians compared to Caucasians.12,13
Patients affected by inborn errors such as
MSUD or GA I in Taiwan were previously reported
to either die early or have poor neurologic out-
comes before the use of MS/MS screening.14,15 In
this and another study,16 this group of patients
obviously had better early outcomes after MS/MS
screening. Similar benefit as a result of MS/MS
tscreening was also reported in a Taiwanese infan
with isovaleric acidemia.17 Interestingly, MS/MS
gscreening also proved to be helpful in improvin
rthe detection of conditions that are screened fo
traditionally, such as hyperphenylalaninemia,
since the earlier start of treatment (Table 3) was
Table 3. Neonatal screening using tandem mass spectrometry (MS/MS) effectively improved the treatment
of hyperphenylalaninemia
BIA (n = 34) MS/MS (n = 7) p
First phenylalanine level (μM) 944 ± 603 (185–2279) 807 ± 334 (329–1150) 0.879
Age at time of treatment (d) 46 ± 23 (17–127) 21 ± 7 (12–30) < 0.001
BIA = bacterial inhibition assay.
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indeed credited to the use of MS/MS, even
though the long-term outcome of these patients
is still too premature to evaluate.
The use of MS/MS in neonatal screening has
expanded our ability to detect more metabolic
disorders. However, this technology also brings up
new situations that require closer and more so-
phisticated interactions between care providers,
laboratory workers, and family members. For ex-
ample, parents of children affected by 3-MCC
deficiency, which is a benign condition, may ex-
press high levels of anxiety after being informed
of the screening results and require extra reassur-
ance. Therefore, standard protocols for patient
management and counseling, tracking of pa-
tients, and collaboration between local hospitals
and referral centers are urgently required.
Our experience with MS/MS screening in
Taiwan has shown that it is a reliable method for
the early diagnosis of many metabolic disorders
and it might also significantly improve the out-
come of some. Moreover, MS/MS screening also
resolved the unique spectrum of metabolic dis-
orders in Taiwan.
References
1. Millington DS, Kodo N, Norwood DL, et al. Tandem mass
spectrometry: a new method for acylcarnitine profiling
with potential for neonatal screening for inborn errors of
metabolism. J Inherit Metab Dis 1990;13:321–4.
2. Baumgartner MR, Almashanu S, Suormala T, et al. The
molecular basis of human 3-methylcrotonyl-CoA carboxy-
lase deficiency. J Clin Invest 2001;107:495–504.
3. Haberle J, Pauli S, Schmidt E, et al. Mild citrullinemia in
Caucasians is an allelic variant of argininosuccinate syn-
thetase deficiency (citrullinemia type 1). Mol Genet Metab
2003;80:302–6.
4. Wiley V, Carpenter K, Wilcken B. Neonatal screening with
tandem mass spectrometry: 12 months’ experience in
NSW Australia. Acta Pediatri Suppl 1999;88:48–51.
5. Wilcken B, Wiley V, Hammond J, et al. Screening neona-
tals for inborn errors of metabolism by tandem mass
spectrometry. N Engl J Med 2003;348:2304–12.
6. Zytkovicz TH, Fitzgerald EF, Marsden D, et al. Tandem
mass spectrometric analysis for amino, organic, and fatty
acid disorders in neonatal dried blood spots: a two-year
summary from the New England Neonatal Screening
Program. Clin Chem 2001;47:1945–55.
7. Schulze A, Lindner M, Kohlmuller D, et al. Expanded
neonatal screening for inborn errors of metabolism by elec-
trospray ionization-tandem mass spectrometry: results, out-
come, and implications. Pediatrics 2003;111:1399–406.
8. Chiang SH, Hsiao YS, Hsiao KJ. Prospective of Neonatal
Screening. In: Lee ML, ed. Taiwan Metabolic disorders—
Taiwan experiences. Taipei: Ho Chi Book Publishing Co.,
2004:29–58.
9. Lin WD, Wu JY, Lai CC, et al. A pilot study of neonatal
screening by electrospray ionization tandem mass spectro-
metry in Taiwan. Acta Paediatr Taiwan 2001;42:224–30.
f10. Rashed MS, Ozand PT, Bucknall MP, et al. Diagnosis o  
inborn errors of metabolism from blood spots by acylcar-
nitines and amino acids profiling using automated electro-
spray tandem mass spectrometry. Pediatr Res 1995;38:
324–31.
f11. Schulze A, Kohlmueller D, Mayatepek E. Sensitivity o
electrospray-tandem mass spectrometry using the pheny-
lalanine/tyrosine-ratio for differential diagnosis of hyper-
phenylalaninemia in neonates. Clin Chim Acta 1999;283:
15–20.
12. Gregersen N, Winter V, Curtis D, et al. Medium-chain
acyl-CoA dehydrogenase (MCAD) deficiency: the prevalent
mutation G985 (K304E) is subject to a strong founder effect
from northwestern Europe. Hum Hered 1993;43:342–50.
13. Wang SS, Fernhoff PM, Hannon WH, et al. Medium chain
acyl-CoA dehydrogenase deficiency human genome epi-
demiology review. Genet Med 1999;1:332–9.
14. Yeung CY, Lin SP, Kao HA, et al. Maple syrup urine disease:
report of two cases. J Formos Med Assoc 1993;92:765–8.
15. Shu SG, Tsai CR, Chen LH, et al. Type I glutaric aciduria:
 phenotypes and genotypes in 5 Taiwanese children.
J Formos Med Assoc 2003;102:729–32.
16. Lin JF, Chiu PC, Hsu HY, et al. An early diagnosis leads 
to a good prognosis: a patient with maple syrup urine
disease—screened by tandem mass spectrometry. Acta
Paediatr Taiwan 2004;45:287–9.
17. Wei CC, Lin WD, Tsai FJ, et al. Isovaleric acidemia diag-
fnosed promptly by tandem mass spectrometry: report o
one case. Acta Paediatr Taiwan 2004;45:236–8.
